Shares of CASI Pharmaceuticals stock traded down $0.11 during trading hours on Friday, reaching $2.98. The company’s stock had a trading volume of 135,543 shares, compared to its average volume of 188,889. CASI Pharmaceuticals has a one year low of $2.73 and a one year high of $5.20. The company has a market capitalization of $285.24 million, a P/E ratio of -9.31 and a beta of 1.12. The stock’s fifty day simple moving average is $3.28 and its two-hundred day simple moving average is $3.19.
CASI Pharmaceuticals (NASDAQ:CASI) last released its quarterly earnings data on Friday, August 9th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). As a group, equities analysts forecast that CASI Pharmaceuticals will post -0.34 earnings per share for the current year.
Several institutional investors have recently added to or reduced their stakes in the business. Susquehanna International Group LLP bought a new position in shares of CASI Pharmaceuticals in the second quarter valued at $81,000. Jane Street Group LLC bought a new position in shares of CASI Pharmaceuticals during the second quarter valued at about $35,000. BlackRock Inc. lifted its position in shares of CASI Pharmaceuticals by 13.6% during the second quarter. BlackRock Inc. now owns 3,111,073 shares of the biotechnology company’s stock valued at $9,955,000 after purchasing an additional 372,964 shares in the last quarter. Northern Trust Corp lifted its position in shares of CASI Pharmaceuticals by 1.0% during the second quarter. Northern Trust Corp now owns 606,766 shares of the biotechnology company’s stock valued at $1,942,000 after purchasing an additional 6,257 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of CASI Pharmaceuticals by 23.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 313,252 shares of the biotechnology company’s stock valued at $1,003,000 after purchasing an additional 59,501 shares in the last quarter. 12.17% of the stock is currently owned by hedge funds and other institutional investors.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc, a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.
Featured Story: Bollinger Bands
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.